Author

A. Ozkul

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Pharmacology & Toxicology· 2 Biochemistry· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:drug response / drug discovery· 4 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Assay:proteomics· 3 Assay:bulk RNA-seq· 1 Assay:metabolomics· 1 Organism:mouse· 1

Frequent Co-Authors

A. Hanifehnezhad· 2 shared A. YILMAZER· 2 shared C. E. Ozcelik· 2 shared C. GURCAN· 2 shared C. V. BITIRIM· 2 shared E. DEMIR· 2 shared E. KOCAKAYA· 2 shared G. Y. SUMMAK· 2 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Hanifehnezhad

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

FABP4 as a Therapeutic Host Target Controlling SARS-CoV2 Infection

H. Baazim, E. Koyuncu, G. Tuncman, M. F. Burak, L. Merkel, N. Bahour, E. S. Karabulut, G. Y. Lee, A. Hanifehnezhad, Z. F. Karagoz, K. Foldes, I. Engin, A. G. Erman, S. Oztop, N. Filazi, , G. S. Hotamisligil

This study identifies FABP4 as a host target that modulates SARS-CoV-2 infection, showing that its inhibition reduces viral replication and lung damage in infected hamsters.

bioRxiv · Feb 10, 2024 · PreprintMicrobiology

Screening Peptide Drug Candidates to Neutralize Whole Viral Agents : A Case study with SARS-CoV-2 Virus

C. E. Ozcelik, C. Z. Araz, O. Yilmaz, S. Gulyuz, A. Ozkul, U. O. S. Seker

The paper uses M13 phage display to identify SARS-CoV-2 neutralizing peptides, finding three candidates with both binding and neutralizing capacity.

bioRxiv · Oct 22, 2023 · PreprintBioengineering

Hemin shows antiviral activity in vitro, possibly through suppression of viral entry mediators.

M. A. UNAL, C. V. BITIRIM, J. SOMERS, G. Y. SUMMAK, O. BUL BESBINAR, E. KOCAKAYA, C. GURCAN, H. NAZIR, Z. B. Aksoy Ozer, S. A. OZKAN, S. BEREKETOGLU, A. OZKUL, E. DEMIR, K. C. AKCALI, A. YILMAZER

This study shows Hemin reduces SARS-CoV-2 infectivity in Vero E6 cells by decreasing TMPRSS2 and ACE2 expression.

bioRxiv · May 24, 2022 · PreprintPharmacology & Toxicology

A Highly Potent SARS-CoV-2 Blocking Lectin Protein

R. E. Ahan, A. Hanifehnezhad, E. Sahin Kehribar, T. C. Oguzoglu, K. Foldes, C. E. Ozcelik, N. Filazi, S. Oztop, S. C. Onder, E. U. Bozkurt, K. Ergunay, A. Ozkul, U. Seker

This paper demonstrates that griffithsin (GRFT) blocks SARS-CoV-2 entry into cell lines and mouse models by binding to the spike protein, suggesting its potential as a prophylactic drug against SARS-CoV-2 variants.

bioRxiv · Jul 22, 2021Biochemistry

High level production and characterization of truncated human angiotensin converting enzyme 2 in Nicotiana benthamiana plant as a potential therapeutic target in COVID-19

T. Mammedov, I. Gurbuzaslan, M. Ilgin, D. Yuksel, G. Mammadova, A. Ozkul, G. Hasanova

This study produces and characterizes truncated human ACE2 in plants, showing it binds SARS-CoV-2 spike protein and has anti-viral activity, with deglycosylated form being more effective.

bioRxiv · May 17, 2021 · PreprintBioengineering

Ribavirin shows antiviral activity against SARS-CoV-2 and downregulates the activity of TMPRSS2 and the expression of ACE2 in vitro

M. A. Unal, C. V. Bitirim, G. Y. Summak, S. Bereketoglu, I. Cevher Zeytin, O. Besbinar, C. Gurcan, D. Aydos, E. Goksoy, E. Kocakaya, Z. Eran, M. Murat, N. Demir, J. Somers, E. Demir, , K. C. Akcali

bioRxiv · Dec 4, 2020Pharmacology & Toxicology